Author:
Das Sujoy,Strachanowska Marcelina,Wadowski Piotr,Juszczak Michał,Tokarz Paulina,Kosińska Aneta,Palusiak Marcin,Rybarczyk-Pirek Agnieszka J.,Wzgarda-Raj Kinga,Vasudevan Saranya,Chworos Arkadiusz,Woźniak Katarzyna,Rudolf Bogna
Abstract
AbstractIn these studies, we designed and investigated the potential anticancer activity of five iron(II) cyclopentadienyl complexes bearing different phosphine and phosphite ligands. All complexes were characterized with spectroscopic analysis viz. NMR, FT–IR, ESI–MS, UV–Vis, fluorescence, XRD (for four complexes) and elemental analyses. For biological studies, we used three types of cells—normal peripheral blood mononuclear (PBM) cells, leukemic HL-60 cells and non-small-cell lung cancer A549 cells. We evaluated cell viability and DNA damage after cell incubation with these complexes. We observed that all iron(II) complexes were more cytotoxic for HL-60 cells than for A549 cells. The complex CpFe(CO)(P(OPh)3)(η1-N-maleimidato) 3b was the most cytotoxic with IC50 = 9.09 µM in HL-60 cells, IC50 = 19.16 µM in A549 and IC50 = 5.80 µM in PBM cells. The complex CpFe(CO)(P(Fu)3)(η1-N-maleimidato) 2b was cytotoxic only for both cancer cell lines, with IC50 = 10.03 µM in HL-60 cells and IC50 = 73.54 µM in A549 cells. We also found the genotoxic potential of the complex 2b in both types of cancer cells. However, the complex CpFe(CO)2(η1-N-maleimidato) 1 which we studied previously, was much more genotoxic than complex 2b, especially for A549 cells. The plasmid relaxation assay showed that iron(II) complexes do not induce strand breaks in fully paired ds-DNA. The DNA titration experiment showed no intercalation of complex 2b into DNA. Molecular docking revealed however that complexes CpFe(CO)(PPh3) (η1-N-maleimidato) 2a, 2b, 3b and CpFe(CO)(P(OiPr)3)(η1-N-maleimidato) 3c have the greatest potential to bind to mismatched DNA. Our studies demonstrated that the iron(II) complex 1 and 2b are the most interesting compounds in terms of selective cytotoxic action against cancer cells. However, the cellular mechanism of their anticancer activity requires further research.
Funder
Interdisciplinary Research Grant of the University of Lodz
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Rosenberg, B., Vancamp, L., Trosko, J. E. & Mansour, V. H. Platinum compounds: A new class of potent antitumour agents. Nature 222, 385–386. https://doi.org/10.1038/222385a0 (1969).
2. Johnstone, T. C., Park, G. Y. & Lippard, S. J. Understanding and improving platinum anticancer drugs–phenanthriplatin. Anticancer Res. 34, 471–476 (2014).
3. Oun, R., Moussa, Y. E. & Wheate, N. J. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans. 47, 6645–6653. https://doi.org/10.1039/c8dt00838h (2018).
4. Fong, C. W. Platinum anti-cancer drugs: Free radical mechanism of Pt-DNA adduct formation and anti-neoplastic effect. Free Radical Biol. Med. 95, 216–229. https://doi.org/10.1016/j.freeradbiomed.2016.03.006 (2016).
5. Lee, S. Y., Kim, C. Y. & Nam, T. G. Ruthenium complexes as anticancer agents: A brief history and perspectives. Drug Des. Devel. Ther. 14, 5375–5392. https://doi.org/10.2147/dddt.s275007 (2020).